Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

Indevus In-Licenses Nebido To Complement Sanctura

Aug. 1, 2005

By Jennifer Boggs

Cerovive NDA Delayed: More Patients Needed For Phase III

July 29, 2005

By Jennifer Boggs

Cerovive NDA Delayed: More Patients Needed For Phase III

July 29, 2005

By Jennifer Boggs

Changes to delay EPIX trial of blood clot imaging agent

July 28, 2005

By Jennifer Boggs

Biogen Idec: Strong Sales Boost Earnings, Tysabri Data Looming

July 28, 2005

By Jennifer Boggs

Biogen Idec: Strong Sales Boost Earnings, Tysabri Data Looming

July 28, 2005

By Jennifer Boggs

Valeant Prepares For Phase III Retigabine Studies In Epilepsy

July 27, 2005

By Jennifer Boggs

Valeant Prepares For Phase III Retigabine Studies In Epilepsy

July 27, 2005

By Jennifer Boggs

Novacea Gains Rights To Oral Vinorelbine From Pierre Fabre

July 26, 2005

By Jennifer Boggs

Novacea Gains Rights To Oral Vinorelbine From Pierre Fabre

July 26, 2005

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 18, 2025.
Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM
BioWorld
The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...
Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study
BioWorld
In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress...
Atai Therapeutics discovers new 5-HT2A receptor partial agonists
BioWorld Science
Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...